{"id":"NCT02926937","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-11","primaryCompletion":"2019-04-22","completion":"2019-05-17","firstPosted":"2016-10-06","resultsPosted":"2021-06-21","lastUpdate":"2021-06-21"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin (SAR439954)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and exercise.\n\nSecondary Objectives:\n\n* To compare Sotagliflozin 400 mg versus placebo based on:\n* Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal.\n* Change from baseline in fasting plasma glucose (FPG).\n* Change from baseline in systolic blood pressure (SBP) for participants with baseline SBP â‰¥130 millimeter per mercury (mmHg).\n* Change from baseline in SBP for all participants.\n* Change from baseline in body weight.\n* Proportion of participants with HbA1c \\<6.5%, \\<7.0%.\n* To compare Sotagliflozin 200 mg versus placebo based on:\n* Change from baseline in HbA1c.\n* Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal.\n* Change from baseline in body weight.\n* Change from baseline in SBP for all participants.\n* To evaluate the safety of Sotagliflozin 400 and 200 mg versus placebo.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo)","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.34,"sd":0.12},{"arm":"Sotagliflozin 400 mg","deltaMin":-1.03,"sd":0.122}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":21},"locations":{"siteCount":70,"countries":["United States","Canada","Mexico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":150},"commonTop":["Headache","Diarrhoea","Urinary tract infection"]}}